CLOSEOUT LETTER
Buderer Drug Company Inc MARCS-CMS 506509 —
- Delivery Method:
- UPS Next Day
- Product:
- Drugs
- Recipient:
-
Recipient NameJames W. Buderer
-
Recipient TitlePresident
- Buderer Drug Company Inc
26611 Dixie Hwy
Ste 119
Perrysburg, OH 43551-1765
United States
- Issuing Office:
- Center for Drug Evaluation and Research
United States
- (313) 393-8100
Dear Mr. Buderer:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (CIN-16-506509-22), dated September 20, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Nicholas F. Lyons
Compliance Director
Division of Pharmaceutical Quality Operations III